Trial Search Results

Phase I CD19/CD22 Chimeric Antigen Receptor T Cells in Peds Recurrent/Refractory B Cell Malignancies

This phase I trial studies the best dose and side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy, and to see how well they work in treating children or young adults with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. A CAR is a genetically-engineered receptor made so that immune cells (T cells) can attack cancer cells by recognizing and responding to the CD19/CD22 proteins. These proteins are commonly found on B acute lymphoblastic leukemia. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CD19/CD22-CAR T cells and chemotherapy may work better in treating children or young adults with B acute lymphoblastic leukemia.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Crystal Mackall, MD

Collaborator: National Cancer Institute (NCI)

Intervention(s):

  • Biological: Chimeric Antigen Receptor T-Cell Therapy
  • Drug: Cyclophosphamide
  • Drug: Fludarabine Phosphate
  • Other: Laboratory Biomarker Analysis
  • Other: Questionnaire Administration

Phase:

Phase 1

Eligibility


1.1 INCLUSION CRITERIA

   1. Diagnosis: ALL In view of the PI and the primary oncologist, there must be no
   available alternative curative therapies or subject has declined to pursue alternative
   therapy; and subjects must be either ineligible for allogeneic stem cell transplant
   (SCT), have refused SCT, recurred after SCT, or have disease activity that prohibits
   SCT at the time of enrollment.

      1. Chemotherapy refractory disease in subjects with B-ALL is defined as progression
      or stable disease after two lines of therapies

      2. Recurrence of disease after achieving a complete response (CR).

      3. Subjects with persistent or relapsed minimal residual disease (MRD) (by flow
      cytometry, PCR, FISH, or next generation sequencing) require verification of MRD
      positivity on two occasions at least 4 weeks apart.

      4. Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia
      (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed
      after two lines of therapy, including tyrosine kinase inhibitors (TKIs).

      5. Subjects with recurrence of isolated CNS relapse after achieving complete
      remission (CR); if relapsed with MRD, will require verification of MRD positivity
      on two occasions at least 4 weeks apart.

   2. Diagnosis: Lymphoma Subjects with lymphoma must have progressed, had SD, or recurred
   after initial treatment regimens that include an anthracycline and an anti CD20
   monoclonal antibody. Subjects who relapse ≥12 months after therapy should have
   progressed after autologous transplant or been ineligible for autologous transplant.

   3. CD19 expression CD19 expression is required at any time since diagnosis. If patient
   has received anti-CD19 targeted therapy (i.e. Blinatumomab), then CD19 expression must
   be subsequently demonstrated. CD19 expression. must be detected on greater than 50% of
   the malignant cells by immunohistochemistry or ≥ 90% by flow cytometry. The choice of
   whether to use flow cytometry or immunohistochemistry will be determined by what is
   the most easily available tissue sample in each subject. In general,
   immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used
   for peripheral blood and bone marrow samples.

   4. Subjects who have undergone autologous SCT with disease progression or relapse
   following SCT will be eligible if all other eligibility criteria are met. Subjects who
   have undergone allogeneic SCT will be eligible if, in addition to meeting other
   eligibility criteria, they are at least 100 days post-transplant, they have no
   evidence of active GVHD and have been without immunosuppressive agents for at least 30
   days.

   5. Subjects who have undergone prior anti-CD19 or anti-CD22 CAR therapy will be eligible
   if < 5% of circulating levels of CD3+ cells express the previous CAR by flow
   cytometry.

   6. Must have evaluable or measurable disease; subjects with lymphoma must have evaluable
   or measurable disease according to the revised IWG Response Criteria for Malignant
   Lymphoma[66] must be present. Lesions that have been previously irradiated will be
   considered measurable only if progression has been documented following completion of
   radiation therapy.

   7. At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any
   prior systemic therapy at the time the subject is planned for leukapheresis, except
   for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5
   half-lives.

   Exceptions:

   f. There is no time restriction with regard to prior intrathecal chemotherapy (incl.
   steroids) provided there is complete recovery from any acute toxic effects of such; g.
   Subjects receiving hydroxyurea may be enrolled provided there has been no increase in
   dose for at least 2 weeks prior to starting apheresis; h. Subjects who are on standard
   ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine or oral methotrexate)
   may be enrolled provided that chemotherapy is discontinued at least 1 week prior to
   apheresis.

   i. Subjects receiving steroid therapy at physiologic replacement doses (≤ 5 mg/day of
   prednisone or equivalent doses of other corticosteroids) only are allowed provided
   there has been no increase in dose for at least 2 weeks prior to starting apheresis;
   j. For radiation therapy: Radiation therapy must have been completed at least 3 weeks
   prior to enrollment, with the exception that there is no time restriction if the
   volume of bone marrow treated is less than 10% and also the subject has
   measurable/evaluable disease outside the radiation port.

   8. Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for
   clinically non-significant toxicities, such as alopecia, nutritional support measures,
   electrolyte abnormalities, or those not impacting the investigator's ability to assess
   treatment emergent toxicities)

   9. Age Greater than or equal to 1 year of age and less than or equal to 30 years of age
   at time of enrollment; must meet parameters for apheresis per institutional
   guidelines. NOTE: The first subject in the first dose cohort must be ≥ 18 years of age
   if an adult has not been treated at that dose cohort on the companion Stanford
   protocol "Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T
   Cells in Adults with Recurrent or Refractory B Cell Malignancies" and undergone safety
   evaluation at Day 28 without evidence of DLT.

10. Performance Status: Subjects > 10 years of age: Karnofsky ≥ 50%; Subjects ≤ 10 years
   of age: Lansky scale ≥ 50% (See Appendix B Section 14.2)

11. Normal Organ and Marrow Function (supportive care is allowed per institutional
   standards, i.e. filgrastim, transfusion)

      1. ANC ≥750/uL*

      2. Platelet count ≥50,000/uL*

      3. Absolute lymphocyte count ≥150/uL*

      4. Adequate renal, hepatic, pulmonary and cardiac function defined as:

         - Serum ALT/AST ≤10 ULN (unless elevated ALT/AST is attributed to leukemia or
         lymphoma involvement of the liver, in which case this criterion will be
         waived and not disqualify a patient).

         - Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.

         - Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant
         pericardial effusion as determined by an ECHO, and no clinically significant
         ECG findings

         - No clinically significant pleural effusion

         - Baseline oxygen saturation >92% on room air at rest

         - creatinine: within age adjusted normal institutional limits (see table
         below) OR

         - creatinine clearance ≥60 mL/min/1.73 m2 (as estimated by Cockcroft Gault
         Equation) for subjects with creatinine levels above institutional normal.

   Age (Years) Maximum Serum Creatinine (mg/dL)

   ≤5 0.8 5 < age ≤ 10 1.0 >10 1.2

   * if these cytopenias are not judged by the investigator to be due to underlying
   disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not
   be excluded because of pancytopenia ≥ Grade 3 if it is due to disease, based on the
   results of bone marrow studies.

12. CNS Status

      1. Subjects with ALL

      Subjects with the following CNS status are eligible only in the absence of
      neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy:

         - CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on
         cytospin preparation, regardless of the number of WBCs;

         - CNS 2, defined as presence of < 5/µL WBCs in CSF and cytospin positive for
         blasts, or > 5/µL WBCs but negative by Steinherz/Bleyer algorithm:

            - CNS 2a: <10/µL RBCs; < 5/µL WBCs and cytospin positive for blasts;

            - CNS 2b: ≥10/µL RBCs; < 5/µL WBCs and cytospin positive for blasts;

            - CNS 2c: ≥10/µL RBCs; ≥5/µL WBCs and cytospin positive for blasts but
            negative by Steinherz/Bleyer algorithm.

      2. Subjects with lymphoma

   Subjects must have no signs or symptoms of CNS disease or detectable evidence of CNS
   disease on MRI at the time of screening. Subjects who have previously been treated for
   CNS disease and who have the following CNS status will be eligible:

      - CNS 1, defined as absence of blasts in cerebral spinal fluid (CSF) on cytospin
      preparation, regardless of the number of WBCs;

      - CNS 2, defined as presence of < 5/µL WBCs in CSF and cytospin positive for
      blasts, or > 5/µL WBCs but negative by Steinherz/Bleyer algorithm:

         - CNS 2a: < 10/µL RBCs; < 5/µL WBCs and cytospin positive for blasts;

         - CNS 2b: ≥ 10/µL RBCs; < 5/µL WBCs and cytospin positive for blasts;

         - CNS 2c: ≥ 10/µL RBCs; ≥ 5/µL WBCs and cytospin positive for blasts but
         negative by Steinherz/Bleyer algorithm.

13. Females of childbearing potential must have a negative serum or urine pregnancy test
   (females who have undergone surgical sterilization or who have been postmenopausal for
   at least 2 years are not considered to be of childbearing potential)

14. Contraception Subjects of child-bearing or child-fathering potential must be willing
   to practice birth control from the time of enrollment on this study and for four (4)
   months after receiving the preparative regimen.

   Females of child-bearing potential must have a negative pregnancy test because of the
   potentially dangerous/unknown effects on the fetus.

15. Ability to give informed consent. All subjects ≥ 18 years of age must be able to give
   informed consent. For subjects <18 years old their legal authorized representative
   (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be
   included in age appropriate discussion and verbal assent will be obtained for those >
   7 years of age, when appropriate.

1.2 EXCLUSION CRITERIA

Subjects meeting any of the following criteria are not eligible for participation in the
study:

   1. Recurrent or refractory ALL limited to isolated testicular.

   2. Subjects with radiologically-detected CNS lymphoma or CNS 3 disease (presence of ≥
   5/µL WBCs in CSF and cytospin positive for blasts [in the absence of a traumatic
   lumbar puncture] and/or clinical signs of CNS leukemia).

   3. Hyperleukocytosis (≥ 50,000 blasts/µL) or rapidly progressive disease that in the
   estimation of the investigator and sponsor would compromise ability to complete study
   therapy.

   4. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g.
   cervix, bladder, breast) unless disease free for at least 3 years.

   5. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or
   requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial
   pharyngitis are permitted if responding to active treatment.

   Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus
   (anti-HCV positive) as the immunosuppression contained in this study will pose
   unacceptable risk. A history of hepatitis B or hepatitis C is permitted if the viral
   load is undetectable per quantitative PCR and/or nucleic acid testing.

   6. CNS disorder such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar
   disease, or autoimmune disease with CNS involvement that in the judgment of the
   investigator may impair the ability to evaluate neurotoxicity.

   7. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or
   other clinically significant cardiac disease within 12 months of enrollment, or have
   cardiac atrial or cardiac ventricular lymphoma involvement.

   8. Subjects receiving anticoagulation therapy.

   9. Any medical condition that in the judgement of the principal investigator is likely to
   interfere with assessment of safety or efficacy of study treatment

10. History of severe immediate hypersensitivity reaction to any of the agents used in
   this study.

11. Women of child-bearing potential who are pregnant or breastfeeding because of the
   potentially dangerous effects of the conditioning lymphodepletion chemotherapy on the
   fetus or infant. Females who have undergone surgical sterilization or who have been
   postmenopausal for at least 2 years are not considered to be of childbearing
   potential.

12. In the investigator's judgment, the subject is unlikely to complete all
   protocol-required study visits or procedures, including follow-up visits, or comply
   with the study requirements for participation.

13. May not have primary immunodeficiency or history of systemic autoimmune disease (e.g.
   Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or
   requiring systemic immunosuppression/systemic disease modifying agents within the last
   2 years.

Ages Eligible for Study

1 Year - 30 Years

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Christin New
650-497-8815
Recruiting